Patent intelligence · US
US 11725043
Ulinastatin polypeptides
Ulinastatin polypeptides
Patent details — US 11725043
- Jurisdiction
- US
- Status
- granted
- Grant date
- Aug 15, 2023
- Expiration
- Aug 10, 2043
- Applicant
- DiaMedica USA Inc.
- Claims
- 27
- CPC classes
- A61K, A61K38/00, A61K38/57, A61P
Quick answer
US 11725043 (Ulinastatin polypeptides) is held by DiaMedica USA Inc.. Status: granted. Granted Aug 15, 2023. Expires Aug 10, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- DiaMedica USA Inc.
- Grant date
- Expiration
- Claims
- 27
- CPC classes
- A61K, A61K38/00, A61K38/57, A61P, A61P1/18, A61P29/00
More from DiaMedica USA Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12329805
Dosage forms of tissue kallikrein 1
granted -
US 11857608
Dosage forms of tissue kallikrein 1
granted -
US 9839678
Human tissue kallikrein 1 glycosylation isoforms
granted -
US 9616015
Formulations of human tissue kallikrein-1 for parenteral delivery and related methods
granted -
US 9364521
Human tissue kallikrein 1 glycosylation isoforms
granted -
US 8673964
Use of drug combinations for treating insulin resistance
granted -
US 8501695
Tissue kallikrein for the treatment of diseases associated with amyloid protein
granted
Frequently asked questions
What is US patent 11725043?
US 11725043 (Ulinastatin polypeptides) is held by DiaMedica USA Inc.. Status: granted. Granted Aug 15, 2023. Expires Aug 10, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11725043?
DiaMedica USA Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 9 pharmaceutical patents for this assignee.
When does US 11725043 expire?
Our index shows an expiration date of Aug 10, 2043 (17 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.